• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email
    SC 13G/A 1 gtcr-sc13ga_111424.htm AMENDMENT TO FORM SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934 

    (Amendment No. 2)*

     

     

     

    Sotera Health Co.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share  

    (Title of Class of Securities)

     

    83601L 102  

    (CUSIP Number)

     

    September 30, 2024  

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

     

    ☐ Rule 13d-1(b) 

     

    ☐ Rule 13d-1(c) 

     

    ☒ Rule 13d-1(d) 

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     

     

    CUSIP No. 83601L 102 Page 2 of 11

     

    1.  

    Names of Reporting Persons

     

    GTCR INVESTMENT XI LLC 

    2.  

    Check The Appropriate Box if a Member of a Group (See Instructions) 

    (a) ☐ (b) ☒ 

     

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    Delaware 

    Number of 

    Shares 

    Beneficially 

    Owned By 

    Each 

    Reporting 

    Person 

    With 

      5.  

    Sole Voting Power

     

    0 

      6.  

    Shared Voting Power

     

    123,038,253 (1) 

      7.  

    Sole Dispositive Power

     

    0 

      8.  

    Shared Dispositive Power

     

    49,215,301 

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    123,038,253 

    10.  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐ 

    11.  

    Percent of Class Represented By Amount in Row (9)

     

    43.4% (2) 

    12.  

    Type of Reporting Person (See Instructions)

     

    OO 

     

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the GTCR Investors are party to a Stockholders Agreement with the Warburg Pincus Investors and certain other holders of Common Stock of the Issuer. The GTCR Investors, together with the Warburg Pincus Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 73,822,952 shares of Common Stock are publicly reported as being owned by the Warburg Pincus Investors in such entities’ Form 4, filed with the U.S. Securities and Exchange Commission (“Commission”) September 9, 2024. Although the GTCR Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the Warburg Pincus Investors as a result of the Stockholders Agreement, each GTCR Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such GTCR Reporting Person. The percentages used herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 3 of 11

     

    1.  

    Names of Reporting Persons

     

    GTCR FUND XI/A LP 

    2.  

    Check The Appropriate Box if a Member of a Group (See Instructions) 

    (a) ☐ (b) ☒ 

     

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    Delaware 

    Number of 

    Shares 

    Beneficially 

    Owned By 

    Each 

    Reporting 

    Person 

    With

      5.  

    Sole Voting Power

     

    0 

      6.  

    Shared Voting Power

     

    123,038,253 (1) 

      7.  

    Sole Dispositive Power

     

    0 

      8.  

    Shared Dispositive Power

     

    39,061,101 

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    123,038,253 

    10.  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐ 

    11.  

    Percent of Class Represented By Amount in Row (9)

     

    43.4% (2) 

    12.  

    Type of Reporting Person (See Instructions)

     

    PN 

     

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the GTCR Investors are party to a Stockholders Agreement with the Warburg Pincus Investors and certain other holders of Common Stock of the Issuer. The GTCR Investors, together with the Warburg Pincus Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 73,822,952 shares of Common Stock are publicly reported as being owned by the Warburg Pincus Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the GTCR Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the Warburg Pincus Investors as a result of the Stockholders Agreement, each GTCR Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such GTCR Reporting Person. The percentages used herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.  
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 4 of 11

      

    1.  

    Names of Reporting Persons

     

    GTCR FUND XI/C LP 

    2.  

    Check The Appropriate Box if a Member of a Group (See Instructions) 

    (a) ☐ (b) ☒ 

     

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    Delaware 

    Number of 

    Shares 

    Beneficially 

    Owned By 

    Each 

    Reporting 

    Person 

    With

      5.  

    Sole Voting Power

     

    0 

      6.  

    Shared Voting Power

     

    123,038,253 (1) 

      7.  

    Sole Dispositive Power

     

    0 

      8.  

    Shared Dispositive Power

     

    9,841,141 

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    123,038,253 

    10.  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐ 

    11.  

    Percent of Class Represented By Amount in Row (9)

     

    43.4% (2) 

    12.  

    Type of Reporting Person (See Instructions)

     

    PN 

     

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the GTCR Investors are party to a Stockholders Agreement with the Warburg Pincus Investors and certain other holders of Common Stock of the Issuer. The GTCR Investors, together with the Warburg Pincus Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 73,822,952 shares of Common Stock are publicly reported as being owned by the Warburg Pincus Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the GTCR Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the Warburg Pincus Investors as a result of the Stockholders Agreement, each GTCR Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such GTCR Reporting Person. The percentages used herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 5 of 11

     

    1.  

    Names of Reporting Persons

     

    GTCR CO-INVEST XI LP 

    2.  

    Check The Appropriate Box if a Member of a Group (See Instructions) 

    (a) ☐ (b) ☒ 

     

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    Delaware 

    Number of 

    Shares 

    Beneficially 

    Owned By 

    Each 

    Reporting 

    Person 

    With

      5.  

    Sole Voting Power

     

    0 

      6.  

    Shared Voting Power

     

    123,038,253 (1) 

      7.  

    Sole Dispositive Power

     

    0 

      8.  

    Shared Dispositive Power

     

    313,059 

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    123,038,253 

    10.  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐ 

    11.  

    Percent of Class Represented By Amount in Row (9)

     

    43.4% (2) 

    12.  

    Type of Reporting Person (See Instructions)

     

    PN 

     

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the GTCR Investors are party to a Stockholders Agreement with the Warburg Pincus Investors and certain other holders of Common Stock of the Issuer. The GTCR Investors, together with the Warburg Pincus Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 73,822,952 shares of Common Stock are publicly reported as being owned by the Warburg Pincus Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the GTCR Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the Warburg Pincus Investors as a result of the Stockholders Agreement, each GTCR Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such GTCR Reporting Person. The percentages used herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 6 of 11

     

    1.  

    Names of Reporting Persons

     

    GTCR PARTNERS XI/A&C LP 

    2.  

    Check The Appropriate Box if a Member of a Group (See Instructions) 

    (a) ☐ (b) ☒ 

     

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    Delaware 

    Number of 

    Shares 

    Beneficially 

    Owned By 

    Each 

    Reporting 

    Person 

    With

      5.  

    Sole Voting Power

     

    0 

      6.  

    Shared Voting Power

     

    123,038,253 (1) 

      7.  

    Sole Dispositive Power

     

    0 

      8.  

    Shared Dispositive Power

     

    48,902,242 

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    123,038,253 

    10.  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐ 

    11.  

    Percent of Class Represented By Amount in Row (9)

     

    43.4% (2) 

    12.  

    Type of Reporting Person (See Instructions)

     

    PN 

     

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the GTCR Investors are party to a Stockholders Agreement with the Warburg Pincus Investors and certain other holders of Common Stock of the Issuer. The GTCR Investors, together with the Warburg Pincus Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 73,822,952 shares of Common Stock are publicly reported as being owned by the Warburg Pincus Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the GTCR Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the Warburg Pincus Investors as a result of the Stockholders Agreement, each GTCR Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such GTCR Reporting Person. The percentages used herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 7 of 11

     

    Item 1(a). Name of Issuer
       
      The name of the issuer is Sotera Health Co. (the “Issuer”).
       
    Item 1(b). Address of the Issuer’s Principal Executive Offices
       
      The Company’s principal executive offices are located at 9100 South Hills Blvd, Suite 300, Broadview Heights, OH, 44147.
       
    Item 2(a)/(b)/(c). Names of Persons Filing
       
     

    This Amendment No. 2 to Schedule 13G is being filed jointly by (i) GTCR Fund XI/A LP, a Delaware limited partnership (“Fund XI/A”), (ii) GTCR Fund XI/C LP, a Delaware limited partnership (“Fund XI/C”), (iii) GTCR Co-Invest XI LP, a Delaware limited partnership (“Co-Invest XI”, and together with Fund XI/A and Fund XI/C, the “GTCR XI Funds or GTCR Investors”), (iv) GTCR Partners XI/A&C LP, a Delaware limited partnership (“Partners XI/A&C”) and the general partner of each of Fund XI/A and Fund XI/C, and (v) GTCR Investment XI LLC, a Delaware limited liability company (“Investment XI”) and the general partner of Co-Invest XI and Partners XI/A&C. Investment XI is managed by a board of managers (the “GTCR Board of Managers”) consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the shares of Common Stock. The GTCR XI Funds, Partners XI/A&C and Investment XI are collectively referred to herein as the “GTCR Reporting Persons”.

       
      The principal business address of each of the GTCR Reporting Persons is 300 North LaSalle Street, Suite 5600, Chicago, IL 60654.
       
    Item 2(d). Title of Class of Securities
       
      Common Stock, par value $0.01 per share (the “Common Stock”).
       
    Item 2(e). CUSIP Number
       
      83601L 102
       
    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):
       
      Not Applicable.
       
    Item 4. Ownership
       
      The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page hereto for each GTCR Reporting Person and is incorporated herein by reference for each such GTCR Reporting Person.
       
      On November 19, 2020, (i) the Issuer, (ii) Warburg Pincus Private Equity XI, L.P., Warburg Pincus Private Equity XI-B, L.P., Warburg Pincus Private Equity XI-C, L.P., WP XI Partners, L.P. and Bull Co-Invest, L.P. (collectively, the “Warburg Pincus Sponsors or Warburg Pincus Investors”), (iii) the GTCR XI Funds and (iv) certain other holders of Common Stock of the issuer (the “Other Investors”), entered into a Stockholders Agreement (the “Stockholders Agreement”). The Stockholders Agreement sets forth certain governance arrangements with respect to the Issuer, transfer restrictions on Other Investors and indemnification matters. Pursuant to the Stockholders Agreement, each of the Warburg Pincus Sponsors and the GTCR XI Funds has agreed to vote the shares of Common Stock of the Issuer that each holds of record in a certain manner on matters related to the election of certain directors appointed by the Warburg Pincus Sponsors and the GTCR XI Funds. The Warburg Pincus Sponsors and the GTCR XI Funds hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), including 49,215,301 shares of Common Stock of the Issuer that are publicly reported as being owned by the GTCR XI Funds and 73,822,952 shares of Common Stock of the Issuer that are publicly reported as being owned by the Warburg Pincus Sponsors. The GTCR Reporting Persons are not entitled to any rights as a stockholder of the Issuer with respect to the shares of Common Stock of the Issuer beneficially owned by the Other Investors or the Warburg Pincus Sponsors except as expressly set forth in the Stockholders Agreement and the GTCR Reporting Persons do not have dispositive power over the Common Stock owned by the Warburg Pincus Sponsors. Each GTCR Reporting Person and each of the individual members of the GTCR Board of Managers expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock of the Issuer other than the shares of Common Stock of the Issuer owned of record by a GTCR Reporting Person. The number of shares of Common Stock of the Issuer owned by each GTCR Reporting Person as set forth in Rows 5 – 11 of their respective cover pages to this Schedule 13G does not reflect the aggregate shares of Common Stock of the Issuer owned by the Other Investors.

     

     

     

     

    CUSIP No. 83601L 102 Page 8 of 11

       
      The aggregate total of 73,822,952 shares of Common Stock of the Issuer indicated in this Amendment No. 2 to Schedule 13G as being beneficially owned by the Warburg Pincus Sponsors is derived from the Warburg Pincus Sponsors’ Form 4, filed with the Commission on September 9, 2024, and is not purported to be an accurate representation of the Warburg Pincus Sponsors’ beneficial ownership as of the date of this Amendment No. 2 to Schedule 13G. The Warburg Pincus Sponsors are responsible for reporting their beneficial ownership of shares of Common Stock of the Issuer on their own behalf, and the GTCR Reporting Persons disclaim responsibility for reporting the shares of Common Stock of the Issuer beneficially owned by the Warburg Pincus Sponsors.
       
      The percentages used herein are calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.
       
    Item 5. Ownership of Five Percent or Less of a Class
       
      Not Applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      (1) The GTCR Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of the Exchange Act. The joint filing agreement among the GTCR Reporting Persons to file this Amendment No. 2 to Schedule 13G jointly in accordance with Rule 13d-1(k) of the Exchange Act is incorporated by reference as Exhibit A.

     

     

     

     

    CUSIP No. 83601L 102 Page 9 of 11

       
      (2) Each GTCR Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock of the Issuer other than the shares of Common Stock of the issuer owned of record by such GTCR Reporting Person.
       
    Item 9. Notice of Dissolution of Group
       
      Not Applicable.
       
    Item 10. Certification
       
      Not Applicable.

     

     

     

     

    CUSIP No. 83601L 102 Page 10 of 11

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024 

       
      GTCR INVESTMENT XI LLC
       
     

    /s/ Jeffrey Wright 

      Name: Jeffrey Wright
      Title: Chief Legal Officer
       
      GTCR FUND XI/A LP
       
     

    /s/ Jeffrey Wright 

      Name: Jeffrey Wright
      Title: Chief Legal Officer of GTCR Investment XI LLC, the general partner of GTCR Partners XI/A&C LP, the general partner of GTCR FUND XI/A LP
       
      GTCR FUND XI/C LP
       
     

    /s/ Jeffrey Wright 

      Name: Jeffrey Wright
      Title: Chief Legal Officer of GTCR Investment XI LLC, the general partner of GTCR Partners XI/A&C LP, the general partner of GTCR FUND XI/C LP
       
      GTCR CO-INVEST XI LP
       
     

    /s/ Jeffrey Wright 

      Name: Jeffrey Wright
      Title: Chief Legal Officer of GTCR Investment XI LLC, the general partner of GTCR CO-INVEST XI LP
       
      GTCR PARTNERS XI/A&C LP
       
     

    /s/ Jeffrey Wright 

      Name: Jeffrey Wright
      Title: Chief Legal Officer of GTCR Investment XI LLC, the general partner of GTCR PARTNERS XI/A&C LP

     

     

     

     

    CUSIP No. 83601L 102 Page 11 of 11

     

    EXHIBIT LIST

     

    Exhibit A Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.*
       

    * Incorporated herein by reference to the Agreement of Joint Filing by GTCR Investment XI LLC, GTCR Fund XI/A LP, GTCR Fund XI/C LP, GTCR Co-Invest XI LP and GTCR Partners XI/A&C LP dated as of February 11, 2022, which was previously filed with the Commission as Exhibit A to Amendment No. 1 to Schedule 13G filed by GTCR Investment XI LLC, GTCR Fund XI/A LP, GTCR Fund XI/C LP, GTCR Co-Invest XI LP and GTCR Partners XI/A&C LP on February 11, 2022 with respect to the shares of common stock of Sotera Health Co.

     

     

    Get the next $SHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/23/2023$6.00 → $18.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $SHC
    Financials

    Live finance-specific insights

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

      2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

      2/27/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:51:55 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:50:09 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/12/24 5:53:58 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sotera Health upgraded by Goldman with a new price target

      Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

      5/5/25 8:27:32 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Goldman initiated coverage on Sotera Health with a new price target

      Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

      12/6/24 8:14:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Piper Sandler initiated coverage on Sotera Health with a new price target

      Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00

      5/21/24 7:45:20 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SHC
    SEC Filings

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results

      SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sites located in the United States and Europe. Nelson Labs' testing solution is unique in that it supports a broad range of both medical devices and pharmaceutical products. This innovative approach broadens the scope of Rapid Sterility Testing—a field that has primarily focused on products with biological components or short shelf life—by providing a vers

      3/4/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Chairman & CEO Petras Michael B. Jr. covered exercise/tax liability with 100,849 shares and was granted 298,953 shares, increasing direct ownership by 30% to 868,603 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 9:49:47 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • President of Sterigenics Rutz Michael P covered exercise/tax liability with 13,284 shares and was granted 48,579 shares, increasing direct ownership by 7% to 576,815 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:38:48 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 6,481 shares and was granted 97,159 shares, increasing direct ownership by 82% to 201,110 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:36:07 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form DEFA14A filed by Sotera Health Company

      DEFA14A - Sotera Health Co (0001822479) (Filer)

      5/2/25 4:05:40 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Sotera Health Company

      10-Q - Sotera Health Co (0001822479) (Filer)

      5/1/25 4:05:19 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sotera Health Co (0001822479) (Filer)

      5/1/25 7:45:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

      CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

      1/6/25 4:30:38 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Appoints Christopher Simon to the Board of Directors

      CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

      8/1/24 7:00:02 AM ET
      $HAE
      $SHC
      Medical/Dental Instruments
      Health Care
      Misc Health and Biotechnology Services
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials